Table 4 Details of post-ESD bleeding and delayed bleeding
SLE group (n = 69) | Non-SLE group (n = 73) | p values | |
|---|---|---|---|
Post-ESD bleeding | 15/69 (21.7%) | 16/73 (21.9%) | 0.98 |
Single antiplatelet | 3/32 (9.4%) | 4/37 (10.8%) | 0.84 |
Single anticoagulant | 1/16 (6.3%) | 3/20 (15.0%) | 0.41 |
Multiple therapy | 11/21 (52.4%) | 9/16 (56.2%) | 0.82 |
Early bleeding | 1/69 (1.4%) | 2/73 (2.7%) | 0.59 |
Delayed bleeding | 14/69 (20.3%) | 14/73 (19.2%) | 0.87 |
Single antiplatelet | 3/32 (9.4%) | 3/37 (8.1%) | 0.85 |
Single anticoagulant | 1/16 (6.3%) | 3/20 (15.0%) | 0.41 |
Multiple therapy | 10/21 (47.6%) | 8/16 (50.0%) | 0.89 |